Conference Coverage
Conference Coverage
For COVID-19 plus diabetes, glycemic control tops treatment list
Tight glucose control led to better results in patients with diabetes and COVID-19.
Conference Coverage
EULAR’s COVID-19 recommendations offer no surprises
The provisional recommendations cover four themes: general measures and preventing SARS-CoV-2 infection, managing patients without COVID-19 and...
Conference Coverage
Age leads COVID-19 hospitalization risk factors in RMDs
Glucocorticoid use, cardiovascular comorbidity, and male gender were also found to increase the risk of hospitalization from COVID-19 in...
Conference Coverage
Most rheumatology drugs don’t increase COVID-19 hospitalization risk
“These results provide, for the first time, information about the outcome of COVID-19 in patients with rheumatic and musculoskeletal diseases.”
Conference Coverage
Need HER2-positive testing in CRC; trastuzumab deruxtecan shows benefit
Conference Coverage
Treating primary tumor doesn’t improve OS in stage IV breast cancer
Conference Coverage
Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphoma
Pembrolizumab should be considered “the preferred treatment option and the standard of care” for patients with classic Hodgkin lymphoma not...
Conference Coverage
Expanding the role of PARP inhibitors in breast cancer
Conference Coverage
Trastuzumab deruxtecan proves active in HER2-mutated NSCLC
The confirmed overall response rate was 61.9%, and the median duration of response has not been reached.
Conference Coverage
Oral relugolix works to a T against advanced prostate cancer
Compared with leuprolide, relugolix reduced testosterone levels more rapidly and was associated with a lower incidence of cardiovascular side...